NCT02281409View on ClinicalTrials.gov

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions
Advanced Solid TumorsMetastatic Solid Tumors
Interventions
BIOLOGICAL

Mogamulizumab (KW-0761)

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Kyowa Hakko Kirin Pharma, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02281409 - Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter